Retatrutide Powder

Retatrutide Raw Material Manufacturer-YTBIO

Retatrutide Powder is a novel peptide-based GLP-1/GIP/glucagon triple receptor agonist that synergistically regulates appetite and energy metabolism. Multiple analyses and trials have confirmed that retatrutide significantly reduces weight, blood pressure, glycated hemoglobin, and lipid levels in obese or overweight adults, and shows therapeutic potential in the remission of non-alcoholic fatty liver disease and cardiovascular-renal-metabolic syndrome.

YTBIO supplies retatrutide with a purity of 98%+ (HPLC). We offer flexible MOQ and customized packaging, and provide corresponding COA and other compliance documents. All production processes adhere to cGMP standards, ensuring high batch-to-batch consistency. Please contact us at any time for the latest quotation and related technical information.

Why Choose YTBIO?

·YTBIO has long focused on functional raw materials and innovative active ingredients, boasting over 12 years of experience serving the international market.

·With our own production and supply system, YTBIO provides customers with more stable quality and cost-effectiveness.

·Our products are sold to multiple countries and regions, adaptable to the diverse needs of different markets in terms of documentation, packaging, and collaboration.

·We support customized packaging and flexible minimum order quantities to meet various development requirements.

·We can provide COA, specification sheets, test reports, and other relevant documents to help you improve procurement and project progress efficiency.

Test Report

What Is Its Mechanism Of Action?

1. Activates GLP-1 receptor
· Promotes insulin secretion
· Inhibits glucagon release
· Delays gastric emptying
· Centrally inhibits appetite

2. Activates GIP receptor
· Synergistically promotes insulin secretion
· Improves insulin sensitivity

3. Activates glucagon receptor
· Increases energy expenditure
· Reduces fat without significantly increasing blood sugar

Potential Health Benefits

Significant weight loss: Average weight loss of 24% over 48 weeks in clinical trials

Powerful blood sugar control: Lowers glycated hemoglobin, effective for type 2 diabetes.

Improved cardiovascular metabolism: Can lower blood pressure and blood lipids, reduce liver fat content, beneficial for non-alcoholic fatty liver disease.

Experiment On Weight Loss With Retatrutide

Generally speaking, weight loss drugs of the glucagon-like peptide-1 receptor agonist (GLP-1A) type, represented by liraglutide injection and semaglutide injection, can reduce body weight by about 8% or 17% during a one-year follow-up period, while the weight loss effect of current bariatric surgery (gastric volume reduction surgery) is also about 30%. The recently launched Retatrutide is a combined agonist of three hormone receptors, namely, the glucagon-like peptide-1 receptor (GLP-1), the glucose-dependent insulinotropic polypeptide receptor (GIP), and the glucagon receptor (GCG). Can this drug bring more obvious weight loss effects? Recently, the NEJM magazine published the results of the Retatrutide Phase II clinical study.

In this phase 2, randomized, controlled, double-blind clinical trial, the researchers enrolled patients with a body mass index (BMI) >= 30 or BMI >= 27 plus at least one obesity-related disease/abnormality. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous weekly injections of Retatrutide (1 mg, 4 mg [initial 2 mg], 4 mg [initial 4 mg], 8 mg [initial 2 mg], 8 mg [initial 4 mg], or 12 mg [initial 2 mg]) or placebo for 48 weeks. The primary endpoint was the percentage change in body weight from baseline at 24 weeks. Secondary endpoints included the percentage change in body weight from baseline to 48 weeks, a weight loss of 5% or more, 10% or more, or 15% or more. Drug safety indicators were also evaluated.

The results showed that of the 338 adults recruited, 51.8% were male. The percentage change in body weight at 24 weeks in the Retatrutide Powder group was -7.2% in the 1mg group, -12.9% in the combined 4mg group, -17.3% in the combined 8mg group, and -17.5% in the 12mg group, while it was -1.6% in the placebo group. At 48 weeks of follow-up, the percentage change in body weight in the Retatrutide group was -8.7% in the 1 mg group, -17.1% in the combined 4 mg group, -22.8% in the combined 8 mg group, -24.2% in the 12 mg group, and -2.1% in the placebo group. At 48 weeks, the proportion of patients who lost more than 5%, more than 10%, and more than 15% of their body weight was 92%, 75%, and 60% in the 4 mg Retatrutide group, 100%, 91%, and 75% in the 8 mg Retatrutide group, 100%, 93%, and 83% in the 12 mg Retatrutide group, and 27%, 9%, and 2% in the placebo group. The most common adverse reactions in the Retatrutide group were gastrointestinal symptoms, which occurred in a dose-related manner, were mostly mild to moderate in severity, and were less common in the group starting with low doses such as 2 mg and 4 mg. Heart rate increased in a dose-dependent manner and declined after reaching a peak at 24 weeks.

Applications

Retatrutide is widely used in peptide research, metabolic health research, drug development, and biotechnology research applications.
 

CONTACT US

Yuantai Organic Bio is committed to providing customers with the highest-quality Retatrutide Powder 98% and services so that every consumer can enjoy natural, healthy, and high-quality food. If you have any inquiries or needs about our products, please feel free to contact us, and we will reply to you as soon as possible.​​​​​​​

Tel:86-029-86478251 / 86-029-86119593
Whatsapp:8617782577059
Email:sales@sxytorganic.com
Office Add: No.801, Building 3, Dahua Shuzhi Industrial Park, Tiangu 6th Road, Yanta District, Xi 'an, Shaanxi，China.